Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult (over the age of 18 years)
Diagnosed with HR+/HER2- metastatic breast cancer
Received at least 1 week of capivasertib + fulvestrant (Patients will be invited to provide documents demonstrating the use of capivasertib. Patients will be able to participate even if unable to obtain such documentation)
You may not be if
Patients who had discontinued capivasertib for more than 6 months before the date of the interview
Unable or unwilling to follow study procedures (including providing informed consent)
Not proficient in spoken English, as assessed by the moderator
Receiving capivasertib in a clinical trial setting
Patients who are not able to recall instruction for administration of capivasertib in a manner consistent with the labeling (e.g. 4 days on followed by 3 days off)
Clareo Health | Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant
